UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
Y Ando, H Saka, G Asai, S Sugiura, K Shimokata… - Annals of …, 1998 - Elsevier
Y Ando, H Saka, G Asai, S Sugiura, K Shimokata, T Kamataki
Annals of Oncology, 1998•ElsevierSummary Background Irinotecan (CPT-11) is metabolized by esterase to form a SN-38,
which is further conjugated by UGT1A1. Genetic polymorphism has been shown in a
promoter region of UGT1A1 and is related to its activity. We investigated whether there might
be an inter-individual difference in pharmacokinetics of SN-38 and its glucuronide,
depending on the genotypes of UGT1A1. Patients and methods Nine male patients with lung
cancer were treated with irinotecan (50 mg/m 2) and carboplatin. Pharmacokinetic …
which is further conjugated by UGT1A1. Genetic polymorphism has been shown in a
promoter region of UGT1A1 and is related to its activity. We investigated whether there might
be an inter-individual difference in pharmacokinetics of SN-38 and its glucuronide,
depending on the genotypes of UGT1A1. Patients and methods Nine male patients with lung
cancer were treated with irinotecan (50 mg/m 2) and carboplatin. Pharmacokinetic …
Background
Irinotecan (CPT-11) is metabolized by esterase to form a SN-38, which is further conjugated by UGT1A1. Genetic polymorphism has been shown in a promoter region of UGT1A1 and is related to its activity. We investigated whether there might be an inter-individual difference in pharmacokinetics of SN-38 and its glucuronide, depending on the genotypes of UGT1A1.
Patients and methods
Nine male patients with lung cancer were treated with irinotecan (50 mg/m2) and carboplatin. Pharmacokinetic parameters were calculated with full sampling plasma data. Genotypes were determined by analyzing the sequence of TATA box of UGT1A1 of genomic DNA from the patients.
Results
The genotyping analysis revealed one heterozygote (6/7) and one homozygote (7/7) for (TA)7TAA allele (UGT1A1*28). The remaining seven patients were homozygote for (TA)6TAA allele (6/6, wild type). The metabolic ratios (SN-38/SN-38 glucuronide) in the patient with 7/7 genotype were uncharacteristically higher than those in the patients with other genotypes (6/6 and 6/7). Biliary index was 6980 versus 2180 ± 1110 (range 840–3730) in patients with 7/7 versus 6/6 genotypes, respectively.
Conclusion
These results support the idea that the patient with 7/7 genotype has an impaired capacity for glucuronidation of SN-38.
Elsevier